Related Experiment Videos
The use of antileukotrienes in paediatrics
A Aprile1, S Lucarelli, B Vagnucci
1Department of Pediatrics, La Sapienza University of Rome, Italy.
Insights
New antileukotriene drugs offer promising treatments for allergic diseases like asthma, atopic dermatitis, and urticaria. These medications help manage both acute symptoms and chronic inflammation, broadening therapeutic options for patients.
Area of Science:
- Immunology
- Pharmacology
- Allergy and Clinical Immunology
Background:
- Allergic diseases, including rhinitis, asthma, and dermatitis, stem from the release of inflammatory mediators like histamine from immune cells.
- Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are key mediators in asthma pathogenesis, causing bronchoconstriction and increased mucus secretion.
- Current allergy treatments are expanding with the introduction of cysteinyl leukotriene antagonists.
Purpose of the Study:
- To review the role of antileukotriene medications in managing allergic diseases.
- To explore the potential of antileukotrienes beyond asthma treatment, including atopic dermatitis and urticaria.
Main Methods:
- Review of recent studies and clinical applications of antileukotriene drugs.
- Analysis of the pharmacological effects of cysteinyl leukotrienes and their antagonists.
Main Results:
- Antileukotrienes demonstrate efficacy in controlling both acute and chronic phases of bronchial asthma in adult patients.
- Preliminary evidence suggests successful use of antileukotrienes in managing atopic dermatitis and urticaria.
Conclusions:
- Antileukotrienes represent a significant advancement in allergy treatment, particularly for asthma.
- Further controlled trials are warranted to confirm and expand the therapeutic applications of antileukotrienes across various allergic conditions.
Abstract:
Allergic diseases include a variety of different illnesses (rhinitis, conjunctivitis, asthma, urticaria, dermatitis) whose physiological and pathological basis is the release of chemical mediators such as histamine, PAF (platelet activating factor), metabolites of arachidonic acid and chemotactic factors from mastocytes, basophils and eosinophils. The numerous drugs used for allergy treatment now include the new pharmacological category of cysteinyl leukotriene antagonists. The cysteinyl leukotrienes (LTC4, LTD4 and LTE4) are chemical mediators of the inflammation involved in the pathogenesis of asthma, the biological effects of which are bronchial constriction and an increase in both mucus secretion and vascular permeability. Recent studies carried out above all on adult patients suggest that antileukotrienes can play an important part not only in the acute phase but also in controlling the chronic development of bronchial asthma. Antileukotrienes have also been successfully used by some authors to control atopic dermatitis and urticaria. Though further controlled testing will be required, these applications broaden the possible range of treatments for allergic disease in all its many aspects.